Twenty years of oncolytic virus development have created a field that is driven by the potential promise of lasting impact on our cancer treatment repertoire. With the field constantly expandingVmore than 20 viruses have been recognized as potential oncolytic virusesV new virus candidates continue to emerge even as established viruses reach clinical trials. They all share the defining commonalities of selective replication in tumors, subsequent tumor cell lysis, and dispersion within the tumor. Members from diverse virus classes with distinctly different biologies and host species have been identified. Of these viruses, 15 have been tested on human glioblastoma multiforme. So far, 20 clinical trials have been conducted or initiated using attenuated strains of 7 different oncolytic viruses against glioblastoma multiforme. In this review, we present an overview of viruses that have been developed or considered for glioblastoma multiforme treatment. We outline the principles of tumor targeting and selective viral replication, which include mechanisms of tumor-selective binding, and molecular elements usurping cellular biosynthetic machinery in transformed cells. Results from clinical trials have clearly established the proof of concept and have confirmed the general safety of oncolytic virus application in the brain. The moderate clinical efficacy has not yet matched the promising preclinical lab results; next-generation oncolytic viruses that are either ''armed'' with therapeutic genes or embedded in a multimodality treatment regimen should enhance the clinical results.
most malignant primary brain tumor, is characterized by rapid and highly invasive growth, histologic and genetic heterogeneity, resistance to most chemotherapeutic drugs, and local recurrence. This inauspicious mix of factors, and the tumor's location in the body's most complex and delicate organ, the brain, pose major challenges for curative therapy. Prognosis is dismal, with a median survival of 12 to 15 months. 1 Notwithstanding recent progress using alkylating agents and tumor vasculatureYtargeting monoclonal antibodies that offer a sur-vival benefit of several months in a subset of patients, 2 overall survival numbers have only improved by a few months during the past 3 decades. Consequently, the development of novel alternative treatment options is crucial. Among these possibilities, the use of oncolytic viruses (OVs) holds substantial promise.
In oncology, the use of viruses as therapeutic agents has been extensively studied in 2 overlapping strategies: gene therapy and oncolytic virotherapy. In gene therapy, the focus is on therapeutic genes and the virus plays an essentialVbut not definingVrole as a gene delivery vehicle. Typically, replicationincompetent highly attenuated viral vectors are used. In a fundamental departure from nonreplicating viral vectors, oncolytic virotherapy uses viruses with a preserved potential for an active viral life cycle. The chief paradigm is tumor-selective conditional viral replication, resulting in lytic tumor cell destruction and release of thousands of viral progeny. Newly released viruses go on to infect neighboring tumor cells, theoretically causing and maintaining a wave of virus attack throughout the tumor. This multiplication of the input dose is a unique feature of oncolytic virotherapy that is not existent in any other form of treatment and leads to a local self-amplification of the therapeutic effect. Consequently, a much lower initial dose of virus would theoretically be required compared with nonreplicating viral vector approaches. The success of oncolytic virotherapy depends on many critical factors, and a formulation of the optimal OV would include the following characteristics: (1) distinct and well-defined mechanism of tumor selectivity, (2) strong cytolytic potential with low nontumor toxicity, (3) potential for systemic application, (4) rapid replication cycle with swift intratumoral spread, (5) accessibility to genetic engineering, (6) easy manufacturing and high-titerstock production, (7) availability of antiviral agents to control unwanted viral spread, (8) genetic stability, (9) no preexisting immunity, and (10) stimulation of anti-tumor immunity.
The concept of virotherapy has a long history of nearly 100 years. 3 In 1912, a woman with cervical cancer showed tumor regression after receiving an attenuated rabies virus vaccine. Additional anecdotal reports of cancer regression associated with concurrent virus infection appeared repeatedly over the intervening years. The modern era of virotherapy commenced in the early 1990s, when advances in technology allowing the generation of recombinant, laboratory-engineered viruses met with an improved molecular-based understanding of virology and cancer genetics. The first laboratory-engineered virus used for oncolytic purposes was based on a herpes simplex virus (HSV) mutant and was reported in 1991 by Martuza et al, 4 followed by an engineered oncolytic adenoviral mutant in 1996. 5 During the course of the last 2 decades, most cancer types have been experimentally targeted by virotherapy, and the list of potential oncolytic viral agents has extended to well over 20 viruses with countless variants and improved successor generations. From the beginning, GBM has been a focus of OV development. This is in large part due to some features that make gliomas particular suitable for OV therapy: (1) They are nearly exclusively confined to 1 organ compartment and distant metastases are not a characteristic of the disease, traits that may be complemented by the potential of OVs for local replication and intratumoral spread. (2) They grow surrounded by mostly postmitotic cells, making it particularly attractive for viruses that require active cell cycles for their replication.
Since the pioneering study of Martuza et al in 1991, more than 250 articles have been published on glioma oncolytic virotherapy, and about 15 viruses have been considered and examined for glioblastoma targeting (Table 1) Figure 1 . In the following, we outline general concepts of oncolytic virotherapy for glioblastoma, present a comprehensive overview of currently investigated OVs for glioblastoma, and list the central findings of previous and ongoing clinical trials.
GENERAL CONCEPTS
Classification of viruses is based on viral families and characteristics of viral genomes and structures. In virotherapy, an additional categorization addresses pathogenicity of an OV in relation to humans. With few exceptions, the viruses discussed herein fall into 1 of 3 groups: (1) human pathogen, (2) humanattenuated vaccine, and (3) nonhuman pathogen. In general terms, rendering a human pathogenic virus suitable for OV therapy requires targeted alterations of viral pathogenicity factors. These genetically engineered alterations result in a virus with selectively disabling mutations that lead to attenuated infection in normal cells, but not in tumor cells. The most widely known examples for OVs with a human pathogen background are HSV and AdV. Viruses based on human vaccine strains also require genetic engineering before application as OVs to enhance tumor targeting. However, given their preexisting attenuated nature, the need to remove pathogenicity factors is less pronounced. Vaccinia, polio, and measles are prominent examples of vaccine viruses developed for glioma virotherapy. Finally, OV candidates with a nonhuman pathogen background do not necessarily require engineering under the premise that they are not associated with human disease, and infection in humans is either transient or nonproductive. In tumor cells, on the other hand, various cellular aberrations result in enhanced permissiveness to replication of otherwise noninfectious viruses. Newcastle disease virus, myxoma virus (Myx), autonomous parvovirus, vesicular stomatitis virus (VSV), Sindbis virus (SIN), pseudorabies virus (PRV), and Seneca Valley virus (SVV) are included in the group of nonhuman pathogenic viruses investigated as therapeutic antiglioma agents.
The defining concept of virotherapy is a conditional, tumorrestricted viral replication with subsequent lysis of tumor cells. This selective replication is based on inherent or engineered mechanisms that exploit tumor cell aberrations for viral propagation. As our understanding of glioblastoma genetics rapidly grows, 6, 7 so do the number of potential molecular targets for virus interactions. The specific mechanisms underlying gliomaselective infection and replication will be discussed in detail for each virus individually in the respective sections below. A collection of the principles and locations of selective tumorYvirus interaction in relation to different cellular compartments (membrane, cytosol, and nucleus) are shown in Figure 2 .
Cell Surface Mechanisms
Viral receptorYmediated attachment is the initial step of virusYcell interaction and a main target for tumor-selective mechanisms. For glioma, a number of associations have been proposed or established: (1) Measles virus receptor CD46 is overexpressed by numerous cancers. 8 (2) Poliovirus coreceptor CD155 is overexpressed on glioma cells. 9 (3) The receptor for Sindbis virus, the 67-kd high-affinity laminin receptor, has been shown to be overexpressed on numerous cancers. 10 In addition to the inherent affinity of some viruses for receptors overexpressed on tumors, virus tropism can be retargeted toward tumor-associated receptors using genetic engineering. Oncolytic viruses have been designed that specifically target epidermal growth factor receptor vIII (EGFRvIII), platelet-derived growth factor receptor, or interleukin 13 receptor (IL-13R) by viral expression of antibody domains or receptor ligands. 11 In another modification, RGD peptide insertion into AdV fiber protein leads to high-affinity binding to integrins > v A 3 and > v A 5 , which are expressed on the surface of several tumors. 12, 13 Finally, narrowing the broad tissue tropism of VSV through glycoprotein pseudotyping has resulted in increased glioma tropism and reduction in neurotoxicity. 14 
Cytosolic Mechanisms
The cytoplasm contains potent antiviral effector elements. Double-stranded RNA formation, commonly seen with RNA viruses that have a cytosolic life cycle, causes activation of cellular antiviral defense mechanisms, most prominently activation of the protein kinase R (PKR) and interferon pathways. Activated PKR inhibits protein synthesis and promotes apoptosis, and interferon signals a downstream cascade leading to the activation of an orchestra of antiviral mediators. Tumor cells often show defects in antiviral defense, which is the basis for oncolysis by VSV, a virus otherwise extremely susceptible to antiviral cellular responses. 15, 16 Defects in the interferon pathway are also responsible for the oncotropism of myxoma virus 17 and others. PKR is a strong inhibitor of viral protein synthesis, and tumors with an activated ras pathway display impaired PKR function. This forms the basis for the oncolytic action of Reovirus 18 and for F 1 34.5 gene-deleted HSV. 19 An activated AKt pathway has been shown to facilitate myxoma infection selectively. 20 A new target for increased tumor selectivity is the altered expression of inhibitory microRNA elements in tumors. Gene expression and replication of VSV or MV containing sequences complementary to normal cell microRNA, such as let-7 or miR7, were strongly attenuated in normal cells but not in tumor cells lacking let-7 or miR7. 21, 22 Nuclear Mechanisms Autonomous parvoviruses require the S-phase of cell division of the host cell for successful replication, 23 thereby reducing infection of postmitotic cells such as neurons. Thymidine kinase (TK) and ribonucleotide reductase (RR)Ydeleted HSV mutants lack the ability to synthesize new nucleotides unless cellular DNA synthesis is active. 24 Adenovirus E1A and E1B genes activate the cell cycle through Rb and p53 binding, respectively. In tumors with defective p53 or Rb function, AdV E1 genes become dispensable, allowing mutant AdVs lacking E1A or E1B genes to selectively replicate. 25 Finally, for some oncolytic DNA viruses, expression of viral genes can be engineered to be under the control of tumor-or tissue-specific promoters, such as Nestin-1, GFAP, or Ki-67. 26 
Extracellular Mechanisms
The application of several viruses, such as HSV, NDV, VSV, reovirus, and others, can activate tumor-targeting effectors of the innate and adaptive immune system that act synergistically and contribute to tumor reduction. 27, 28 In addition, VSV and vaccinia OVs have been shown to preferentially infect tumor vasculature. 29, 30 Finally, tumor-associated proteases in the extracellular matrix augment the activity of measles and other OVs. 31 
ONCOLYTIC VIRUS CANDIDATES FOR HIGH-GRADE GLIOMA
In the second section, we present a comprehensive collection of OVs with proposed or established antiglioma activity.
Herpes Simplex Virus
Herpes simplex virus 1 (HSV-1) is the prototypic member of the Herpesviridae, a family of large double-stranded DNA viruses, and is a common human pathogen that establishes lifelong infection through latency. Approximately two thirds of the adult population is seropositive for HSV. In 1991, the first experimental application of a genetically modified oncolytic replication-competent virus for glioblastoma was reported by Martuza et al, 4 using an HSV-TKYdeficient mutant, HSVdlsptk, 32 that was shown to be highly attenuated in nondividing cells such as neurons but effective in infecting, killing, and replicating in U87 human glioblastoma in vitro and in vivo. Since then, a multitude of oncolytic HSV mutants have been isolated or engineered, with R3616, HSV-1716, hrR3, G207, and G47$ being the most studied examples for targeting glioblastoma. All these mutants feature deleted or manipulated viral genes that reduce neurotoxicity but do not interfere with infection of actively dividing cells, particularly those with activated Ras pathway signaling and suppressed PKR function. 19, 33 R3616 and HSV-1716 have deletions in both copies of the viral F 1 34.5 genes, the gene product of which is essential for neurovirulence. 34, 35 Another attenuation principle is used by hrR3, a U L 39 gene mutant with disrupted viral RR function, vital for viral nucleotide synthesis in postmitotic but not dividing cells. 36 With a significantly attenuated ability to infect neurons, R3616, HSV-1716, and hrR3 still effectively infect, kill, and replicate in several human glioma samples. 37Y40 Subsequently, second-and third-generation oncolytic HSV recombinants were introduced featuring multimutated genotypes. G207 combines the deletion of both copies of the F 1 34.5 gene with a gene-disrupting lacZ reporter gene insertion into the U L 39 gene resulting in a highly attenuated HSV variant. 41 Antiglioma activity in preclinical studies and an extensive safety assessment in rodents and nonhuman primates resulted in a clinical trial of an oncolytic HSV for glioblastoma that commenced in February 1998. 42 In parallel, HSV-1716 was tested in a clinical study in Europe. 43 G207 is also the foundation for the third-generation HSV G47$ in which a third mutation was added. 44 Deletion of the gene encoding for ICP47 results in enhanced MHC class I antigen presentation and enhanced lymphocytic tumor infiltration. In addition, this deletion causes a promoter shift for the US11 gene resulting in a faster viral life cycle and higher titers of oncolytic HSV progeny, ultimately increasing G47$'s oncolytic activity while preserving G207's safety profile. 45 ''Arming'' a F 1 34.5 gene-deleted HSV with immune-stimulatory IL-12 is the basis for oncolytic candidates designated M002 (murine IL-12) and M032 (human IL-12) and has been shown to enhance glioma cell killing in syngeneic and xenograft tumor models. 46 On the basis of these findings, a clinical trial of M032 has been initiated (NSC 733972).
Additional efforts to ''arm'' attenuated HSV include adding alternative therapeutic transgenes and/or increasing tumorselective targeting through receptor targeting and tumor-specific promoters. Transgenes that have been used include CYP2B1, interleukins, and others. 47Y49 For receptor targeting, an IL-13R>2Y directed HSV was created. 50 In addition, a nestin promoter driving viral F 1 34.5 gene expression was shown to enhance glioma selectivity. 51 Adenovirus A double-stranded nonenveloped DNA virus, AdV is a very common human pathogen that causes mild and self-limiting upper respiratory symptoms. Genetically engineered recombinants of AdV serotype 5 (Ad5) that show conditional replication (CRAds) are some of the most studied OVs. The 36-kb genome of the virus can be divided into 2 sets of genes, early (functional) and late (structural). Early gene products interact with cellular control and defense mechanisms and are indispensable for viral replication in normal cells. Of importance, proteins from the E1A gene region trigger cells to enter S-phase by interacting with cellular retinoblastoma tumor suppressor protein (pRb) and p300; E1B proteins suppress apoptosis by binding and inactivating p53, thereby inhibiting its proapoptotic response; E2 elements control viral DNA replication; E3 proteins counter various antiviral immune responses; and E4 gene products inhibit cellular DNA repair mechanisms and apoptosis. 52 This reliance on activated and uninhibited cell cycle mechanisms for viral replication renders AdVs with E1A or E1B deficiencies replication incompetent in normal cells, and therefore tumor selective. A conditionally replicating E1B 55-kd gene deleted mutant dl1520 Adenovirus 5 (also known as ONYX-015) 5 was effective in killing p53 mutant U373 glioma cells but not p53 normal U87 cells. 53 However, later studies in glioma tissue originating from primary tumor samples reported increased oncolytic activity of ONYX-015 in p53 wild-type glioma xenografts compared with p53 mutants. 54 ONYX-015 was tested in a glioblastoma clinical trial. 55 In addition to p53 targeting, Ad5 mutants have been developed in parallel, which exploit defects in the Rb pathway through amino acid deletions in the Rb binding site of E1A, 56 the resulting CRAd being designated Ad-delta-24. Alterations in expression levels of Rb and p16 were reported in nearly 50% of gliomas, 57 and some reports suggest a correlation with advanced stages of glioma. 58 In addition, receptor retargeting efforts have resulted in modifications of AdV tropism. An RGD peptide inserted into the Ad fiber proteinVwhich normally binds the Coxsackie-Adenovirus receptor CARVled instead to high-affinity binding to integrins > v A 3 and > v A 5 , which have been found on many tumor surfaces. 12 A combined Ad-delta-24 with RGD modifications was shown to have increased oncolytic action against glioblastoma 13 and is currently undergoing testing in a clinical trial (NCT00805376). Additional retargeting strategies include a single chain antibody tagged to the AdV fiber knob that is directed against epidermal growth factor receptor, which resulted in highly selective targeting of glioblastoma. 59 The next generation of Ad-delta-24 includes the addition of an E2F1-responsive element as the promoter for E1A, making adenoviral E1A expression dependent on the presence of free E2F, commonly seen in tumors. This Ad-delta24-RGD-E2F1 construct (also known as ICOVIR) displayed enhanced efficacy in gliomas. 60 
Newcastle Disease Virus
This is an avian paramyxovirus with a negative stranded RNA genome which is not associated with any serious human disease. Five strains PV701, 73-T, MTH-68/H, NDV-HUJ, and V4UPM have been tested for oncolytic potential. 61, 62 The tumorsuppressive nature of NDVas an OVand a tumor vaccine has been extensively studied in in vivo models and in clinical trials. However, the mechanisms underlying tumor selectivity are not well defined. As with other OVs, exploitation of defects in antiviral defense is likely to play a role. 63 An activated Ras pathway might also contribute to NDV oncolysis. 64 In addition, peripheral induction of TNF-> secretion by mononuclear cells and a boost in anti-tumor immune response have been proposed. 65 In stark contrast to most other OV candidates, NDV received relatively little preclinical investigation before being tested in clinical trials. We found only 4 experimental glioma studies, 62,66Y68 along with 4 clinical studies on NDV application against glioblastoma, with some promising reported outcomes. 69Y71 A fifth clinical trial is scheduled to start soon (NCT01174537).
RNA genome, which, together with double-stranded viral RNA transcripts, cause a strong activation of cellular PKR pathways. PKR in turn blocks viral replication through the inhibition of protein synthesis and promotion of apoptosis. Wild-type reovirus displays an oncoselectivity for tumors with an activated Ras signaling pathway, 72 which inhibits PKR function and is initially activated through receptor tyrosine kinases downstream of EGFR and platelet-derived growth factor receptor. Reovirus showed promise as an antiglioma agent in vitro 73 and in vivo. 18 All 16 human glioma specimens and more than 80% of established glioma cell lines tested were susceptible to reovirus oncolysis. Direct intratumoral injection resulted in effective oncolysis in subcutaneous and intracranial human glioblastoma xenografts in immunocompromised nude mice. Neurotoxicity initially observed in immunocompromised animals was absent in immune-competent rodent glioma models, and nonhuman primates injected intracranially with Good Manufacturing Practicegrade reovirus showed no neurotoxicity or measurable adverse effect, 74 paving the way for 2 clinical trials. 75 A recent study showed reovirus oncolytic effect against glioma generalized among several reovirus strains, 76 opening the possibility for potentially repetitive application of serotype-switched reoviruses.
Vaccinia Virus
Vaccinia virus (VV) is closely related to bovine poxvirus and is the vaccine agent used for the smallpox eradication program. It is a large double-stranded enveloped DNA virus with a life cycle restricted to the nonnuclear cytoplasm.
A number of diverse strains of VV have been used as vaccines in humans. 77 Of those, strongly attenuated strains show impaired replication and are mostly used as gene therapy vectors. In contrast, less attenuated VV strains Western Reserve, Lister, and Copenhagen have been used as the basis for recombinantly engineered OVs. Although not regarded as tumor selective in a narrow sense by some authors, 78 studies have shown a certain oncopreference by virtue of transformed cells providing a more favorable environment for VV replication. 79 The first VVs studied for antiglioma activity were armed with a p53 transgene. 80 To enhance oncoselectivity, recombinant VV strains were developed with targeted alterations to the VV genome, including thymidine kinase (TK) deletion and vaccinia growth factor deletion. Application of double-deleted VVs (vvDD) combined with immunosuppressive agents resulted in prolonged survival in rodent glioma models 81 and intravenous injection of vvDD in nonhuman primates was tolerated with no adverse effect. 82 Recently, a VV (JX-594) armed with immunemodulatory human granulocyte macrophage colony stimulating factor and LacZ inserted and disrupting TK gene was shown effective in prolonging survival in animal glioma models. 83 
Poliovirus
Poliovirus is a positive stranded RNA virus belonging to the Picornaviridae family and is the causative agent for human poliomyelitis. Neurotoxicity of poliovirus is attributed to 2 factors: (1) selective binding to the poliovirus receptor PVR (alternatively Necl-5 or CD155) expressed on motor neurons and (2) an internal ribosomal entry site (IRES) at the 5 ¶ end of the viral RNA genome. Importantly, the receptor PVR/CD155 was found to be expressed in a majority of glioblastoma samples tested. 9 In 1996, Gromeier et al 84 introduced an engineered intergenetic poliovirus with curtailed neurotoxicity by replacing the polio IRES sequence with a nonpathogenic version from human rhinovirus type 2. The resulting poliovirus chimera PV1(RIPO) and PVS(RIPO) (with the attenuated Sabin polio vaccine strain as a backbone) showed good oncolytic potential against glioma in vitro and in vivo, 85 although lacking poliomyelitis-like neurotoxicity in safety studies on CD155 transgenic mice and nonhuman primates. 86, 87 PVS(RIPO) has received an Investigational New Drug application number for phase I clinical trials (no. 14735) and is scheduled to enter clinical trials in the upcoming months.
Measles Virus
Measles virus is a negative stranded RNA virus belonging to the Paramyxoviridae family and is a well-known human pathogen causing common exanthemous disease and, in rare circumstances, severe encephalitis. 88 Although early reports of MV growth on cultured glioma cells date back to 1975, 89 it was not until 2003 that the highly attenuated Edmonston strain (MV-Edm) used for widespread vaccination campaigns was shown to be of potential therapeutic value as an oncolytic agent for glioma. 90 The 2 MV glycoproteins, the hemagglutinin protein H and fusion protein F, are crucial for oncolytic specificity and efficacy. Mutations in the viral H protein of the Edmonston strain cause the attenuated virus to display a high affinity to cellular CD46 receptors, which are overexpressed in a broad range of tumors. 8, 91 The F protein is responsible for membrane fusion leading to syncytia formation and, ultimately, apoptosis. 92 In 2002, a recombinant MV-Edm was engineered to express carcinoembryonic antigen (CEA) as a reporter gene to monitor viral activity in vivo. 93 MV-CEA showed a favorable oncolytic and safety profile in a number of animal models including direct intracranial injection in CD46 transgenic mice and nonhuman primates 94 leading to the initiation of a phase I clinical trial for glioblastoma that is currently ongoing (NCT00390299). Recently, retargeted MVs have been engineered to express either a single-chain antibody against glioblastoma-associated antigen EGFRvIII or IL-13 as a ligand to glioblastoma-specific receptor IL-13R>2. 95, 96 
Vesicular Stomatitis Virus
Vesicular stomatitis virus is an enveloped negative stranded RNA virus of the rhabdovirus family that is associated with mild and usually self-limiting disease in livestock. Infection in humans is rare and usually asymptomatic. As one of the most interferon (IFN)-sensitive viruses, infections are rapidly controlled by normal cells that mount an IFN-mediated antiviral response. 97 Vesicular stomatitis virus was introduced as a potent oncolytic candidate in 2000 when it became apparent that VSV's exquisite IFN sensitivity complemented the frequent aberrations in the IFN pathway in tumor cells 15, 98 ; a large number of various tumors were targeted and lysed by VSV, including glioblastoma. Vesicular stomatitis virus has an extremely broad species and tissue tropism due to ubiquitous receptor binding, and it is not confined to specific transforming mutations like p53, ras, or myc. 99 Numerous cancer types have been successfully targeted in preclinical studies. 100 This broad tropism is particularly important in light of the heterogeneous mutation background of GBM. In a recent study, we analyzed the susceptibility of a panel of human glioblastoma cell lines to VSV infection and found various levels of interferon impairment in these tumors but not in nontumor human brain samples. 16 In orthotopic glioma models in rodent brain, VSV applied systemically was shown to selectively target and infect not only the tumor bulk but also remote satellite glioma cell clusters. 101, 102 A limitation to current efforts to develop VSV for potential therapeutic applications in the therapy of glioblastoma is the potential neurotoxicity observed in some rodent models. 103 Consequently, 1 research focus has been on attenuating strategies, which have resulted in several mutants with reduced neurotoxicity. For example, VSV-M51 is a mutant that yields an enhanced interferon response, 104 and VSV-p1-GFP displays a reduced replication speed. 105 In addition, ''armed'' VSVs carrying therapeutic transgenes have been engineered 106, 107 ; however, none of these variants have been examined on glioblastomas yet. Alternatively, evolutionary pressure applied to VSV propagated in glioblastoma cultures resulted in the isolation of VSV-rp30, a mutated variant with enhanced tumor infectivity and lytic potency. 108 Recently, a new VSV construct pseudotyped with a glycoprotein from lymphocytic choriomeningitis virus in place of VSV's natural G protein was introduced with significantly reduced neurotoxicity in mice. 14 Vesicular stomatitis virus has recently been approved for a clinical trial as a vaccine vector for human immunodeficiency virus (NCT01438606) and is in preclinical development as an oncolytic agent for a number of peripheral cancers. 109 A close relative to VSV is Maraba virus, which recently excelled in a comparison study of the oncolytic potential of numerous rhabdovirus variants. Among the tumor lines targeted was human glioblastoma SNB19 (identical to U-373), which was particularly susceptible to Maraba virus infection. 110 
Autonomous Parvovirus
Members of the family Parvoviridae are small nonenveloped single-stranded DNA viruses and, with the exception of human parvovirus B19, are not pathogenic in humans. Parvoviruses can be divided into dependoviruses, such as adenoassociated virus (AAV), which require coinfection with adenovirus, herpesvirus, or other helper viruses for replication, and autonomous parvoviruses that replicate independent of other viruses on permissive cells. A key requirement for virus replication is an inherent dependence on cell replication. 23 In addition, PKR disruption in transformed cells has been proposed to facilitate productive parvovirus infection. 111 Rat H1 parvovirus has been extensively studied for glioblastoma oncolysis in vitro and in vivo 112 and is currently being tested in a phase I clinical study for glioblastoma in Germany 113 (NCT01301430). Another parvovirus, minute virus of mice was subject to basic infectivity studies on glioblastoma cultures, but it has not yet advanced to in vivo studies. 108, 114, 115 
Myxoma Virus
Like vaccinia virus, Myx belongs to the Poxviridae family and is a species-specific pathogen in European rabbits. As such, disease and preexisting immunity in humans have not been reported. 116 Myx was found, however, to overcome the species barrier to selectively infect diverse human tumor cells. The oncotropism was shown to be based on tumor-associated aberrations such as overexpression of Akt. 20 Defects in the interferon pathway also contribute to permissiveness of myxoma infection in nonhost species cells. 17 Myx infected a large number of human glioma cell lines and human glioma surgery specimens; significantly prolonged survival was observed in Myx-injected immunocompromised intracranial glioma xenograft models. 117 In immunocompetent glioma models, intratumoral injection of Myx was effective in conjunction with the immune modulator rapamycin. 118 
Seneca Valley Virus
SVV-001 was initially discovered as a cytolytic cell culture contaminant. Subsequent isolation and sequencing revealed a strong relation to porcine picornaviruses, small single-stranded RNA viruses. The virus is not known to cause any disease in humans or animals, but testing of a human tumor panel revealed a broad spectrum of cytolytic action, particularly on tumors with neuroendocrine features. 119 Human glioblastoma cell lines, however, were mostly resistant (only 2 of 9 lines were substantially infected). Nevertheless, discussing this virus in the context of glioblastoma virotherapy is merited for 2 reasons. First, it shows a strong affinity for pediatric tumors, and a 50% response rate (2/4) in glioblastoma was found in a cell line panel of the Pediatric Preclinical Testing Program. 120 Second, medulloblastoma, the most common pediatric brain tumor, was strongly targeted by SVV. The virus also targeted CD133 + cancer stem cells. 121 In a remarkably fast development from virus isolation to clinical testing, 3 clinical trials were initiated for SVV under the trade name NTX-010 by Neotropix, Inc, including 1 trial for pediatric tumors (NCT01048892).
Sindbis Virus
This alphavirus from the Togaviridae family is a positive stranded RNA virus with birds as the natural host and mosquitoes as the transfer vector. Infection in humans can occur after transmission through mosquito bites. Wild-type SIN is neurotropic, causing encephalitis in mice, but also displays an inherent tropism for tumor cells, 122 which is attributed to one of the surface receptors required for Sindbis virus infection, the 67-kd high-affinity laminin receptor. 123 This receptor has been shown to be overexpressed in numerous cancers 10 and often correlates with more aggressive oncologic features. 124 As a blood-borne pathogen, it is stable in the bloodstream and suitable for systemic application. 125 The attenuated laboratory SIN strain AR339 has been studied as an oncolytic agent for numerous cancers. 126 Our laboratory tested AR339 on glioblastoma and found productive infection of human U87 cells but no infection in a second line, MO59J. 108 
Pseudorabies Virus
Despite its name, PRV is not related to rabies virus but rather to HSV. Pseudorabies virus is a neurotropic pig alphaherpesvirus and the causative agent for Aujetzky disease in pigs. It is nonpathogenic in humans but displays a wide species tropism for infection of mammalian cells beyond its natural host. 127, 128 Pseudorabies virus is widely used in laboratories to study herpesvirus biology and is commonly used as a neuroanatomic circuit-tracing tool, owing to its well-defined transsynaptic spread. 129 Its close relation to human herpesvirus HSV without any known human pathogenicity led to initial studies addressing PRV's potential as an OV. Using the laboratory strain PRV-Bartha as a backbone, several attenuated mutants have been engineered with TK and RR gene deletions analog to attenuated HSV mutants. These PRV variants were shown to infect a number of cancer cell lines in vitro and in vivo; however, affinity for human glioblastoma cells was low. 130 Comparative studies in our laboratory found PRV only moderately suitable as an antiglioma virotherapy agent. Infection of human glioblastoma required a high-viral titer and showed little selectivity over normal human control cells. 108 In vivo, intratumoral viral spread was limited to the injection site, and analysis after systemic virus application found few signs of successful targeting of intracranial glioma xenografts. 102 
CLINICAL TRIALS AND CASE STUDIES Overview
As of the end of 2011, results from 8 clinical trials and 3 case reports have been published: 5 trials using HSV strains G207 and 1716, 1 trial using AdV ONYX-015, 1 trial using reovirus Reolysin, 1 trial using NDV strain HUJ, and 3 case series using NDV strain MTH-68. A total of nearly 120 patients were included in these trials. The important and encouraging outcome of all trials was the absence of any major virus-related complications and the assessment that no dose-limiting toxicity or maximum tolerated dose (MTD) was reached in any trial. Because these early studies were addressing safety and feasibility of this novel approach to treatment, dosing and application regimens were chosen conservatively in most cases, and the overall therapeutic effect was marginal, although some individual cases of treatment response were reported. Individual completed and ongoing trials are discussed in the following paragraphs. See Table 2 for a summary.
Herpes Simplex Virus
Two different oncolytic HSV-1 strains (G207 and 1716) have undergone phase I and II testing, and further phase III studies are on the way. Two other HSV therapeutics (G47delta and M032) are scheduled to enter clinical trials. Two phase I studies were conducted using G207 and a total of 27 patients were enrolled. In these studies published in 2000 and 2008, Markert et al 42 reported no significant toxicity. In the first study, no serious adverse events were observed, and MTD was not reached after intratumoral injection of G207 in 21 patients. Eight of the 21 patients had a positive clinical response, and 1 patient had long-term survival (95.5 years). In the follow-up phase Ib study, 1.15 Â 10 9 plaque-forming units (pfu) of G207 were injected intratumorally or into the tumor bed before or after tumor resection in 6 patients with recurrent GBM. 131 The authors reported that viral replication inside the tumor occurred in only 50% of the patients, and no clinical response was observed in these 6 patients. A third study on intratumoral injection of 10 9 pfu of G207 into 5 different loci inside the tumor, followed by radiotherapy on the next day has been completed, and publication of results is awaited (NCT00157703).
In parallel to G207 trials in the United States, 3 phase I clinical trials using HSV-1716 (SEPREHVIR\; Virttu Biologics) have been conducted in Europe, and the first report was published simultaneously to the first G207 study in 2000 in the same issue of the journal Gene Therapy. A total of 33 patients were enrolled in these trials. In the first study, Rampling et al 43 administered a single injection of 10 3 to 10 5 pfu intratumorally in 9 patients with GBM with no resultant toxicities, and the MTD was not reached. Three patients had long-term survival longer than 3 years. Papanastassiou et al 132 performed a single intratumoral injection of 10 5 pfu of HSV-1716 in 12 GBM patients and subsequent tumor resection 4 to 9 days after injection. In the third study, Harrow et al 133 injected 10 5 pfu into the peritumoral parenchyma in 12 patients with no resultant toxicity. Reportedly, a phase II study is in preparation in Europe (www.virttu.com).
A clinical phase I trial applying a third-generation oncolytic HSV strain G47delta to patients with progressive GBM was initiated at the University of Tokyo in 2009 49 and is currently open for recruitment with a target sample size of 21 patients (World Health Organization trial number JPRN-UMIN000002661).
The latest representative of oncolytic HSV strains ''armed'' with a human IL-12 transgene, designated M032, is scheduled to enter clinical phase I for recurrent or progressive GBM, anaplastic astrocytoma, or gliosarcoma at the University of Alabama in Birmingham (Gene Transfer Protocol Report 0801-899).
Adenovirus
A phase I trial conducted with intratumorally injected ONYX-015 was reported by Chiocca et al 55 in 2004. Twentyfour patients with recurrent malignant glioma received up to 10 10 pfu at 10 different sites at the tumor resection border. No significant toxicity was noted. ONYX-015 application was not associated with a therapeutic effect.
Currently, a phase I study using intratumoral and peritumoral injection of 10 9 to 10 11 pfu of double-modified Ad-Delta-24-RGD (DNATrix) is open for recruitment at MD Anderson Cancer Center in Houston, TX (NCT00805376).
Reovirus
Reovirus (Reolysin; Oncolytics Ltd) has been tested in 2 dose-escalation phase I studies conducted in Canada and the United States. Forsyth et al 75 injected 10 7 to 10 9 pfu of reovirus to 3 intratumoral sites in 12 patients (9 grade 4 and 3 grade 3 gliomas) with recurrent malignant glioma. No significant toxicity was reported and the MTD was not reached. There was 1 patient with a more than 6-year survival. A second multicenter trial in the United States with a dose-escalating design and convection-enhanced delivery of reovirus was done on 18 patients, and no dose-limiting toxicity was reported. Stable disease in 3 patients and partial response in 1 patient were noted, but no formal report has been published yet (NCT00528684).
Newcastle Disease Virus
One formal phase I study and several case reports/series on the use of NDV against glioblastoma have been published. Freeman et al 71 reported a phase I study conducted in Israel on 14 patients with recurrent GBM (including 1 pediatric patient) using intravenously administered lentogenic (highly attenuated) NDV strain HUJ daily for 8 cycles. Eleven patients completed the trial. A total of 1 complete response and 3 long-term survivals (93 years) were reported. No significant toxicity was reported, and the MTD was not reached. A follow-up phase I/II trial at the same institution has been initiated with a target enrollment of 30 patients, who are proposed to receive daily intravenous injection of NDV-HUJ (NCT01174537). Csatary et al have published 3 case reports/series from Hungary using the mesogenic (medium virulent) MTH-68/H NDV strain. They first reported the case of a 14-year-old boy with recurrent GBM who was treated more than 2 years with a combination of chemotherapy and MTH-68/H. 69 The second report was that of 1 adult and 3 pediatric patients with GBM 70 with reported long-term survival. The third case report was that of MTH-68/H and valproic acid in a pediatric patient with anaplastic astrocytomas. 134 These case reports are encouraging; however, a better understanding of underlying mechanisms of action, and a randomized patient selection will benefit future studies of NDV. No formal clinical trials were reported with MTH-68/H so far.
H1 Parvovirus
So far, H1 is the only parvovirus that has reached clinical studies. A phase I study involving intratumoral injection of H1-PV (ParvOryx; Oryx GmbH & Co. KG) before tumor resection has recently been started at the University of Heidelberg in Germany and is expected to enroll 19 patients with progressive primary or recurrent GBM (NCT01301430). The first patient reportedly received treatment in October 2011.
Measles Virus
A phase I study using measles Edmonston vaccine strain derivate expressing human CEA (MV-CEA) in patients with recurrent GBM was initiated at Mayo Clinic in Rochester, MN, and is currently recruiting patients to a planned enrollment number of 40 subjects. The virus is injected intratumorally or into the resection cavity (NCT00390299). 87 The proposed protocol includes single intratumoral convection-enhanced virus application before tumor resection in a dose-escalation design.
CONCLUSIONS
Despite an impressive number of preclinical studies and valuable clinical trials confirming the general safety of the approach, the preclinical promise from laboratory experiments has not yet translated to significant therapeutic impact at the bedside. Given widespread initial hesitation at the use of replication competent lytic viruses in the treatment of the human brain, the decision to focus on the safest and most attenuated agents was paramount for the future of the field of OV therapy. In this regard, the lack of virus-attributable adverse effects in over 100 patients should be considered a success and a foundation for next-generation studies. However, the field cannot survive on promise alone, particularly in light of the substantial costs involved with GMP grade virus production and testing. Without well-demonstrated efficacy that is required to reach treatment approval, the pharmaceutical industry and investment groups will remain cautious. So far, only 1 OV has been approved by a governmental agency, AdV ONYX-015, registered in China for head and neck cancer therapy. 135 Future trials will also incorporate multimodality treatment to investigate synergistic relationships between OVs and standard radiation or chemotherapeutic regimens, which have already been established in numerous preclinical models. 136 An increasing number of studies have recently shown enhanced oncolytic activity when virus application is coupled with agents that temporarily suppress the antiviral immune response. 137 As nicely discussed in a recent commentary on the current state of oncolytic virotherapy, 138 the development of OVs preferably does not follow a unidirectional path but rather benefits from a reiterative feedback loop in which the findings from clinical trials influence and inform the design in future generations of viruses. This is particularly true for virotherapy in the brain, a field that faces unique challenges that can only incompletely be addressed in preclinical laboratory studies. Unlike small-molecule therapeutics, biologic effects of viruses are highly dependent on the species examined. Human viruses such as HSV, AdV, or poliovirus are highly attenuated in rodent tumor models but might be less so when applied in humans. Conversely, nonhuman pathogens such as VSV, SIN, and PRV can be pathogenic in mice, making preclinical survival studies particularly challenging. As these nonhuman pathogens move into clinical trials, a new dimension of safety considerations emerges as the consequences of environmental contamination and spread would need to be considered. 139 Despite the challenges and tremendous efforts involved in developing OVs from ''bench to bedside,'' pursuing this path is justified given not only the potential efficacy of this treatment modality but also the accelerating rate of progress.
